IN8bio, Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. IN8bio serves customers in the United States.

424B3 | Prospectus

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

IN8bio (INAB US)

424B3 | Prospectus

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

S-3 | Registration statement for specified transactions by certain issuers

Current Report (Form 8-K | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-09-06)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)